The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.
Stephen Maxted Ansell
Research Funding - Seattle Genetics; Takeda
Anas Younes
Consultant or Advisory Role - Seattle Genetics; Takeda
Honoraria - Seattle Genetics; Takeda Pharmaceuticals International Co.
Joseph M. Connors
Research Funding - Seattle Genetics
Andrea Gallamini
No relevant relationships to disclose
Won Seog Kim
Consultant or Advisory Role - Celltrion
Jonathan W. Friedberg
Consultant or Advisory Role - Seattle Genetics
Tatyana A. Feldman
Honoraria - Seattle Genetics
Research Funding - Seattle Genetics; Takeda
Graham Collins
Consultant or Advisory Role - Takeda
Honoraria - Takeda
Nancy Bartlett
No relevant relationships to disclose
Jingyuan Wang
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Kelly Brady
Employment or Leadership Position - Takeda
Jessica Sachs
Employment or Leadership Position - Takeda
Dirk Huebner
Employment or Leadership Position - Takeda
Stock Ownership - Takeda
Naomi N. H. Hunder
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
John Radford
Consultant or Advisory Role - Takeda
Honoraria - Seattle Genetics; Takeda